Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (331-340 of 388) with videos related to

Pageof 39
Sort By:
European Urology|November 9, 2021
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 TrialLaurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2025
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 studyGiandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, et al.
JCO Global Oncology|July 8, 2025
Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 StudyMimma Rizzo, Andrey Soares, Shilpa Gupta, et al.
Breast (Edinburgh, Scotland)|July 26, 2024
Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP studyCaterina Caminiti, Giuseppe Maglietta, Laura Arenare, et al.
British Journal of Cancer|August 30, 2017
CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomasMaeva Dufies, Sandy Giuliano, Julien Viotti, et al.
Clinical Genitourinary Cancer|August 1, 2020
Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective StudyMaria Giuseppa Vitale, Stefania Pipitone, Marta Venturelli, et al.
The New England Journal of Medicine|July 25, 2008
Sorafenib in advanced hepatocellular carcinomaJosep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, et al.
European Urology Oncology|February 26, 2023
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell CarcinomaBradley McGregor, Daniel M Geynisman, Mauricio Burotto, et al.
Cancer Medicine|February 21, 2025
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective ExperienceMimma Rizzo, Franco Morelli, Yüksel Ürün, et al.
The Lancet. Oncology|November 28, 2012
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 studyArmando Santoro, Lorenza Rimassa, Ivan Borbath, et al.
Pageof 39

Showing results (331-340 of 388) with videos related to

Sort By:
Pageof 39
European Urology|November 9, 2021
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 TrialLaurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2025
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 studyGiandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, et al.
JCO Global Oncology|July 8, 2025
Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 StudyMimma Rizzo, Andrey Soares, Shilpa Gupta, et al.
Breast (Edinburgh, Scotland)|July 26, 2024
Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP studyCaterina Caminiti, Giuseppe Maglietta, Laura Arenare, et al.
British Journal of Cancer|August 30, 2017
CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomasMaeva Dufies, Sandy Giuliano, Julien Viotti, et al.
Clinical Genitourinary Cancer|August 1, 2020
Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective StudyMaria Giuseppa Vitale, Stefania Pipitone, Marta Venturelli, et al.
The New England Journal of Medicine|July 25, 2008
Sorafenib in advanced hepatocellular carcinomaJosep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, et al.
European Urology Oncology|February 26, 2023
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell CarcinomaBradley McGregor, Daniel M Geynisman, Mauricio Burotto, et al.
Cancer Medicine|February 21, 2025
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective ExperienceMimma Rizzo, Franco Morelli, Yüksel Ürün, et al.
The Lancet. Oncology|November 28, 2012
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 studyArmando Santoro, Lorenza Rimassa, Ivan Borbath, et al.
Pageof 39